MedDataX Logo

Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation

NCT ID: NCT04336501

Last Updated: 2020-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Allogeneic hematopoietic stem cell transplantation (allo-hsct) for the treatment of refractory recurrent acute b-lymphoblastic leukemia (b-all), the overall survival rate of 3 years after transplantation was about 10%. The overall survival rate at 3 years was about 70 percent. In the early stage, the investigators established the monitoring method of leukemia micro-residual disease, effectively screened out the high-risk group of recurrence, combined with the new relapse treatment method, successfully implemented the stratification and even personalized dry prediction of leukemia recurrence for the first time in the world, and reduced the recurrence rate of the high-risk group by 30%. However, the therapeutic targeting is not strong, and up to 30% of patients will develop graft versus host disease, which seriously affects the survival of patients. The use of CAR repair T cells (CAR T) to target CD19 in the treatment of refractory recurrent b-all was effective, and the use of CAR T in the treatment of recurrent b-all after transplantation did not increase the risk of GVHD. This clinical study mainly discussed the safety and efficacy of donor targeted cd19-t cells after allo-hsct in the treatment of acute b-lymphocytic leukemia with minimal residual disease. It is expected that the recurrence rate will be reduced while the incidence of acute GVHD after transplantation will not be increase

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IM19 CAR-T group

Subject will be treated with IM19 car-t cells

Group Type EXPERIMENTAL

IM19 CAR-T

Intervention Type BIOLOGICAL

All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IM19 CAR-T

All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To be aged 3 to 65 years
* It was consistent with the diagnosis of CD19+ B-All with MRD+ in allo- hsct transplantation
* The immunotyping was determined to be CD19+ B-All
* The T lymphocytes in the subjects were 100% donor T lymphocytes
* No chemotherapy or antibody treatment was received 2 weeks before cell therapy
* Left ventricular ejection fraction (LVEF) ≥50% and centerless inclusion were diagnosed by echocardiography
* The subjects had no pulmonary active infection
* Blood oxygen saturation at the fingertips ≥ 92%
* Estimated survival of \>3 months
* ECOG physical condition level 0\~1

Exclusion Criteria

* Unwilling to accept IM19 CAR-T cell therapy, do not agree to signInformed consent of subject
* Subjects are allergic to the components of cellular products
* Total serum bilirubin ≥ 2.0mg/dl、Serum albumin \< 35g/L、ALT and AST were more than 3 times of the upper limit of the normal range. Blood creatinine ≥ 2.0mg/dl;Platelet \< 20 x 109 / L
* Subjects had activity level II-IV aGVHD, or activityModerate to severe cGVHD
* The subjects had a severe failure to control the infection
* Subject with known central nervous system leukemia (CNS2 or CNS3)
* Subjects were treated with CAR T cells or DLT after transplantation
* The subjects developed bone marrow failure syndrome after allo-hsct transplantation
* The subjects had previously received other gene treatments
* The subjects had a history of alcohol, drug use or mental illness
* Subjects were enrolled in any other clinical investigator within 1 month prior to screening
* Female subjects: 1) were pregnant/lactating, or 2) had a pregnancy plan during the study period,Or 3) fertile and unable to use effective contraception
* The researchers believe there are other conditions that may not be appropriate for the study
Minimum Eligible Age

3 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

xiang yu zhao, MD

Role: PRINCIPAL_INVESTIGATOR

Peking University people's hospita

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University people's hospita

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

xiang yu zhao, MD

Role: CONTACT

Phone: 13520122292

Email: [email protected]

zheng li xu

Role: CONTACT

Phone: 13501338951

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

xiang yu zhao, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

YMCART20190423

Identifier Type: -

Identifier Source: org_study_id